Elsevier

NeuroImage

Volume 53, Issue 1, 15 October 2010, Pages 37-43
NeuroImage

Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism

https://doi.org/10.1016/j.neuroimage.2010.06.009Get rights and content

Abstract

People with the apolipoprotein-Eε4 (APOE-4) genetic risk for Alzheimer's disease show morphologic differences in medial temporal lobe regions when compared to non-carriers of the allele. Using a high-resolution MRI and cortical unfolding approach, our aim was to determine the rate of cortical thinning among medial temporal lobe subregions over the course of 2 years. We hypothesized that APOE-4 genetic risk would contribute to longitudinal cortical thickness change in the subiculum and entorhinal cortex, regions preferentially susceptible to Alzheimer's disease related pathology. Thirty-two cognitively intact subjects, mean age 61 years, 16 APOE-4 carriers, 16 non-carriers, underwent baseline and follow-up MRI scans. Over this relatively brief interval, we found significantly greater cortical thinning in the subiculum and entorhinal cortex of APOE-4 carriers when compared to non-carriers of the allele. Average cortical thinning across all medial temporal lobe subregions combined was also significantly greater for APOE-4 carriers. This finding is consistent with the hypothesis that carrying the APOE-4 allele renders subjects at a higher risk for developing Alzheimer's disease.

Research highlights

►The APOE-4 allele is associated with medial temporal cortical thinning in healthy people. ►APOE-4 allele carriers compared to non-carriers show greater cortical thinning in the subiculum and entorhinal region over a two2-year interval. ►High resolution MRI can reveal subregional medial temporal cortical thickness changes in healthy subjects.

Introduction

Alzheimer's disease (AD) has multiple and interacting etiologic factors. The ε4 allele of the apolipoprotein E gene (APOE-4) on chromosome 19 is the only well-established genetic risk factor for sporadic AD (Brouwers et al., 2008). Carrying the APOE-4 allele is associated with higher risk for developing AD and earlier age of onset (Corder et al., 1993). However, the APOE-4 allele does not cause the disease, and the relatively high prevalence in the general population suggests antagonistically pleiotropic effects, which can be found in many genetic variants (Wright et al., 2003).

Neuroimaging studies have revealed structural and functional brain differences among cognitively healthy APOE-4 carriers when compared to non-carriers. Using functional magnetic resonance imaging (fMRI), Bookheimer et al. (2000) found increased magnitude and extent of brain activation during tasks requiring memory in healthy APOE-4 carriers compared to non-carriers. Other fMRI data support these findings (Bondi et al., 2005). Positron emission tomography (PET) reveals reduced glucose metabolism associated with APOE-4 genetic risk in healthy people (Reiman et al., 2005). Cognitively normal APOE-4 carriers also show increased uptake of the amyloid binding ligand PIB (Reiman et al., 2009) and the amyloid and tau binding ligand FDDNP (Small et al., 2009) when compared to subjects not carrying the risk allele.

Advances in spatial resolution and image analysis techniques allow examining regional brain characteristics that might be associated with AD risk in the normal population. This work may contribute to identifying people at greater risk for future cognitive decline. It may also enhance understanding of the relationship between AD risk factors, regional brain structure, and cognitive performance. Hippocampal atrophy is known to be associated with memory impairment and AD (de Leon et al., 1996, Rusinek et al., 2003), but it remains controversial whether hippocampal atrophy is present in healthy people due to APOE-4 genetic risk (Cherbuin et al., 2008, Jack et al., 1998, Mueller et al., 2008). Recent data have shown that when compared to volumetry, medial temporal lobe (MTL) cortical thickness measures may provide better representation of associations between APOE genetic variants and MTL structure changes, given the laminar organization of the cerebral cortex, and the expected subtlety of changes within healthy subjects (Burggren et al., 2008). Cortical thickness measurements have been used to assess structural cortical changes with reasonable accuracy and reliability across many diseases, including memory disorders (Bakkour et al., 2009, Thompson et al., 2003). While several MRI studies have documented reduced volume (Apostolova et al., 2006, Devanand et al., 2007) and cortical thinning (Morra et al., 2009, Thompson et al., 2007) in mild cognitive impairment (MCI) and AD subjects, there has been very little work done examining longitudinal MRI changes in healthy volunteers with a genetic risk for AD.

One approach developed in our laboratory examines subregions of the MTL system using high-resolution MRI combined with cortical unfolding. First applied to the visual cortex (Engel et al., 1997), we adapted this procedure to the MTL (Ekstrom et al., 2009a, Zeineh et al., 2000, Zeineh et al., 2001). This approach uses high-resolution MRI images and increases the visibility of the convoluted MTL cortex while allowing us to measure cortical thickness directly and separately across subregions of the MTL. Using this approach, Burggren et al. (2008) identified reduced cortical thickness in the subiculum (SUB) and entorhinal cortex (ERC) among healthy elderly APOE-4 carriers.

Because APOE proteins are differentially involved in neuronal repair and plasticity processes (Teter et al., 2002), we predict greater decline in neural integrity during the aging process in APOE-4 carriers. In the present study, we used the cortical unfolding approach to identify cortical thinning in a 2-year follow-up among cognitively intact elderly subjects with and without the APOE-4 allele. We hypothesized that subjects with the APOE-4 genetic risk would show increased cortical thinning over time in SUB and ERC, regions susceptible to AD pathology.

Section snippets

Subjects

Thirty-two subjects (16 APOE-4 carriers, 16 non-carriers) participated in this study, which was performed at the Semel Institute for Neuroscience and Human Behavior and the Ahmanson-Lovelace Brain Mapping Center, University of California, Los Angeles. All participants gave written informed consent in accordance with the UCLA Human Subjects Protection Committee procedures. Participants were selected from a pool of 130 control, MCI and AD subjects recruited though advertisements that underwent

Results

There were no significant differences in the neuropsychological test scores between groups at baseline. As shown in Table 1, 2 years later no performance changes could be detected. APOE-4 carriers and non-carriers were equivalent in cortical thickness at baseline, which allowed us to specifically examine the effects of genotype on longitudinal change. We did not find an association between cortical thickness change and cognitive change.

Within-group cortical thickness results: subjects not

Discussion

Our data indicate that among cognitively healthy APOE-4 carriers the rate of cortical thinning over time is significantly greater in SUB and ERC when compared to non-carriers of the APOE-4 allele. Global cortical thinning (average across subregions) was also significantly greater among APOE-4 carriers. Within group, non-APOE-4 carriers did not show cortical thinning over time whereas APOE-4 carriers showed decrease in cortical thickness in all subregions except CA23DG.

The APOE-4 allele is

Disclosure statement

Dr. Small reports having served as a consultant and/or having received lecture fees from Abbott, Brainstorming Co., Dakim, Eisai, Forest, Myriad Genetics, Novartis, Ortho-McNeil, Pfizer, Radica, Siemens, and Medivation. Dr. Small also reports having received stock options from Dakim. Dr. Ercoli reports having received lecture fees from the Alzheimer's Association Speakers Bureau and Keiro Senior Health Services. Other investigators have no financial interests.

Acknowledgments

The authors thank Ms. Andrea Kaplan and Ms. Debbie Dorsey for help in subject recruitment, data management, and study coordination. Supported by NIH grants P01-AG025831, AG13308, P50 AG 16570, MH/AG58156, MH52453, AG10123, and M01-RR00865; General Clinical Research Centers Program; Fran and Ray Stark Foundation Fund for Alzheimer's Disease Research; and Larry L. Hillblom Foundation. Markus Donix was funded by the Max Kade Foundation. No company provided support of any kind for this study.

References (49)

  • M.M. Zeineh et al.

    Application of cortical unfolding techniques to functional MRI of the human hippocampal region

    Neuroimage

    (2000)
  • L.G. Apostolova et al.

    3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease

    Brain

    (2006)
  • A. Bakkour et al.

    The cortical signature of prodromal AD. Regional thinning predicts mild AD dementia

    Neurology

    (2009)
  • M.W. Bondi et al.

    fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease

    Neurology

    (2005)
  • S.Y. Bookheimer et al.

    Patterns of brain activation in people at risk for Alzheimer's disease

    N Engl J. Med.

    (2000)
  • H. Braak et al.

    Neuropathological stageing of Alzheimer-related changes

    Acta Neuropathol. (Berl)

    (1991)
  • N. Brouwers et al.

    Molecular genetics of Alzheimer's disease: an update

    Ann. Med.

    (2008)
  • H. Buschke et al.

    Evaluating storage, retention, and retrieval in disordered memory and learning

    Neurology

    (1974)
  • H.A. Cameron et al.

    Restoring production of hippocampal neurons in old age

    Nat. Neurosci.

    (1999)
  • K. Chen et al.

    Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates

    Am. J. Psychiatry

    (2007)
  • N. Cherbuin et al.

    Total and regional gray matter volume is not related to APOE*E4 status in a community sample of middle-aged individuals

    J. Gerontol. A Biol. Sci. Med. Sci.

    (2008)
  • R.M. Cohen et al.

    Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women

    Neurology

    (2001)
  • E.H. Corder et al.

    Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

    Science

    (1993)
  • M.J. de Leon et al.

    In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease

    Ann. NY Acad. Sci.

    (1996)
  • Cited by (0)

    View full text